FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 306 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Wine Racks and the Mystery of Survival September 16, 2022 The Barriers to Care Faced by LGBTQ People With Cancer: An... January 21, 2021 Mom Fights Second Round Of Breast Cancer — Weeks Later, Her... September 13, 2019 Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality... November 10, 2023 Load more HOT NEWS Breast Cancer Patients with Low Breast Density May Be More Likely... Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why... Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer... FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma...
